Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors
Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Romano D, Gerard C, Poizat F, Niccoli P, Barlier A,
Keywords: neuroendocrine tumors, drug resistance, proteomics, kinases, apoptosis,
Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) result in tumour growth stabilization, eventually followed by tumour progression. Thus, despite their original characteristics, NETs exhibit similar resistance features to treatments than other more common tumours.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Romano D
Authors: Romano D, Gerard C, Mondielli G, Lisbonis C, Niccoli P,
Keywords: Neuroendocrine Tumors, Drug resistance, Proteomics, Kinases,
Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Romano D
Authors: Mohamed A, Romano D, Poizat F, Delpero J, Niccoli P,
Keywords: pNETs primary culture, everolimus, somatostatin analogues, cell viability, chromogranin A secretion, Akt activity,
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Raymond E
Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Raymond E, Harmon C, Niccoli P, Metrakos P, Borbath I,
Keywords: Sunitinib, phase 3, pancreatic neuroendocrine tumor, Ki-67 index, prior treatment, prognostic factor,